Contributions on the topics listed in the Conference Announcement under Section C are welcome as oral or poster presentations. All submissions, apart from invited papers, must present original work, ...

All titles, abstracts, photos and YouTube presentations will need your research mentor’s approval prior to submitting your abstract. The abstract will be open to public viewing. Submit your abstract ...

The American Society for Engineering Education (ASEE) Rocky Mountain Section (RMS) invites the submission of papers, extended abstracts, presentations, posters, workshops and lightning talks for the ...

The ongoing PROTECT Study is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400mg of sparsentan, compared to ...

All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA staff assistance will be immediately available when submitters need it. If you begin your ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company’s NeXT Personal ® whole ...

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster ...

Breadth of Data Demonstrates Growing Real-World Adoption and Clinical Importance of CareDx Testing Solutions in Heart and Lung Transplant Patient Management New SHORE Study Findings Demonstrate that ...

Sparsentan is an investigational product candidate in Phase 3 clinical development that has a dual mechanism of action combining endothelin receptor type A blockade with angiotensin receptor blockade.

Arbutus Biopharma Corporation announced that five abstracts, including a late-breaker, have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam from May 7 to 10, 2025. The ...

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the ...

You must submit your abstract using the online submission form. Abstracts sent by email will not be considered. Abstracts that are incomplete will not be considered. All ESA Annual Meeting proposal ...